KR20240165963A - Tyk2 억제제 및 이의 용도 - Google Patents

Tyk2 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20240165963A
KR20240165963A KR1020247032947A KR20247032947A KR20240165963A KR 20240165963 A KR20240165963 A KR 20240165963A KR 1020247032947 A KR1020247032947 A KR 1020247032947A KR 20247032947 A KR20247032947 A KR 20247032947A KR 20240165963 A KR20240165963 A KR 20240165963A
Authority
KR
South Korea
Prior art keywords
compound
patient
psoriasis
hours
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032947A
Other languages
English (en)
Korean (ko)
Inventor
앨런 존 콜리스
비나약 호사그라하라
바스카르 스리바스타바
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20240165963A publication Critical patent/KR20240165963A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247032947A 2022-03-25 2023-03-24 Tyk2 억제제 및 이의 용도 Pending KR20240165963A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263269943P 2022-03-25 2022-03-25
US63/269,943 2022-03-25
US202263371033P 2022-08-10 2022-08-10
US63/371,033 2022-08-10
US202363490664P 2023-03-16 2023-03-16
US63/490,664 2023-03-16
PCT/US2023/064902 WO2023183901A1 (en) 2022-03-25 2023-03-24 Tyk2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20240165963A true KR20240165963A (ko) 2024-11-25

Family

ID=88102041

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032947A Pending KR20240165963A (ko) 2022-03-25 2023-03-24 Tyk2 억제제 및 이의 용도

Country Status (10)

Country Link
US (1) US20250213572A1 (enExample)
EP (1) EP4499104A4 (enExample)
JP (1) JP2025510813A (enExample)
KR (1) KR20240165963A (enExample)
AU (1) AU2023237900A1 (enExample)
CA (1) CA3246157A1 (enExample)
CL (1) CL2024002824A1 (enExample)
MX (1) MX2024011693A (enExample)
TW (1) TW202345799A (enExample)
WO (1) WO2023183901A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024263861A2 (en) * 2023-06-23 2024-12-26 Dana-Farber Cancer Institute, Inc. Methods of treating chronic lymphocytic leukemia
EP4780462A1 (en) * 2023-09-21 2026-07-29 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
CN122341608A (zh) * 2023-11-24 2026-07-03 苏州科睿思制药有限公司 Zasocitinib的晶型及其制备方法和用途
WO2026032374A1 (zh) * 2024-08-07 2026-02-12 正大天晴药业集团股份有限公司 含联环的化合物用于治疗银屑病的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317854A (en) * 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
US11357775B2 (en) * 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors

Also Published As

Publication number Publication date
MX2024011693A (es) 2024-11-08
US20250213572A1 (en) 2025-07-03
CA3246157A1 (en) 2023-09-28
EP4499104A1 (en) 2025-02-05
AU2023237900A1 (en) 2024-10-10
JP2025510813A (ja) 2025-04-15
EP4499104A4 (en) 2025-09-03
TW202345799A (zh) 2023-12-01
CL2024002824A1 (es) 2025-02-14
WO2023183901A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
JP7724241B2 (ja) Ｉｒａｋ分解剤の結晶形態
US20250213572A1 (en) Tyk2 inhibitors and uses thereof
US20260049095A1 (en) Deuterated stat3 degraders and uses thereof
TWI783978B (zh) Tyk2抑制劑、其用途及生產方法
KR102717819B1 (ko) Tyk2 억제제 및 이의 용도
JP7699052B2 (ja) Ｔｙｋ２阻害剤およびその使用
KR20250083546A (ko) Irak4 분해자의 염 형태
TW202216156A (zh) 全身紅斑性狼瘡之治療
WO2024064080A1 (en) Stat6 degraders and uses thereof
US20250215002A1 (en) Solid forms of tyk2 inhibitors and methods of use
US20240262830A1 (en) Ire1a modulators and uses thereof
JP2025510844A (ja) Ｔｙｋ２阻害剤の合成及びその中間体
US20250221997A1 (en) Tyk2 inhibitor formulations and methods of making the same
CN118973583A (zh) Tyk2抑制剂及其用途
WO2025062372A1 (en) Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
JP2025503491A (ja) Ｏｘｅｒ１アンタゴニスト及びその使用
HK1232801B (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
HK1232801A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000